Stock Market News To Give You An Edge

Proven Track Record of Most Accurate Analysis

Stock Market News
To Give You An Edge​

Proven Track Record
of Most Accurate Analysis

COMPLETELY INDEPENDENT AND OBJECTIVE

The Arora Report, Ltd. is a rare publisher that does not accept advertisements. This way The Arora Report can not be influenced. The Arora Report also does not accept payments from any company that is the subject of the posts. The Arora Report has forsaken millions of dollars in revenues to avoid conflicts of interest. Our sole job is to help you. Read more.

COMPLETELY INDEPENDENT AND OBJECTIVE

The Arora Report, Ltd. is a rare publisher that does not accept advertisements. This way The Arora Report can not be influenced. The Arora Report also does not accept payments from any company that is the subject of the posts. The Arora Report has forsaken millions of dollars in revenues to avoid conflicts of interest. Our sole job is to help you. Read more.

WE MADE MONEY IN THE WORST MAY IN A HALF CENTURY

We publish in real time two separate and distinct models. In addition, we also separately  publish in real time   individual  trades  from long time frames to very short term to illustrate the power of the ZYX Change Method. In all three, not only we made money, we significantly outperformed in the worst month in a half century. IN MAY ZYX LONG SHORT EQUITIES ALLOCATION MODEL BEAT S&P 500 BY 22.90% The model worked better than we expected. Since its inception in 2007 to May 7, 2010, the model updated allocation only six times and never used hedging.  In May, inputs to the model

Read More »

ANATOMY OF THE SHORT TERM $GENZ (GENZYME) TRADE

Stock price of Genzyme spiked on the news that  FDA granted approval to  Lumizymethel (aglucosidase alfa) for the treatment of late onset Pompe disease. Pompe disease is a rare  and often fatal condition that disables the heart and muscles due to deficiency of an enzyme called alpha-glucosidase (GAA). Lumizyme, marketed outside the US as Myozyme is approved for the treatment of Pompe disease in about 45 countries  and is available in the US for the treatment of infants and children. Approval of Lumizymethe was expected on Jun 17, 2010. The only surprise was that the approval came  about three weeks early.  The strong up move in the stock price apparantley was the result of investors

Read More »

EXITING $GENZ WITH PROFIT AT $49.30

www.thearorareport.com THE ARORA REPORT, Ltd. HOME OF THE UNIQUE ZYX CHANGE METHOD DEDICATED SOLELY TO PROFIT FROM CHANGE BY TRADING AND INVESTING VERIFIABLE PERFORMANCE RECORD Every closed trade since 2007, without exception, is included in the performance results. Number of winning positions: 162 Number of losing positions: 10 Average annualized % return per position: 296.77% ………………Check out details .

Read More »

NEW UPDATES ON BOTH ALLOCATION MODELS

New updates to both allocation models have been posted on the Allocation Model page. www.thearorareport.com THE ARORA REPORT, Ltd. HOME OF THE UNIQUE ZYX CHANGE METHOD DEDICATED SOLELY TO PROFIT FROM CHANGE BY TRADING AND INVESTING VERIFIABLE PERFORMANCE RECORD Every closed trade since 2007, without exception, is included in the performance results. Number of winning positions: 162 Number of losing positions: 10 Average annualized % return per position: 296.77% ………………Check out details .

Read More »

USE ZYX CHANE METHOD TRRADE MANAGEMENT GUIDELINES TO PROTECT PROFITS ON $GENZ

www.thearorareport.com THE ARORA REPORT, Ltd. HOME OF THE UNIQUE ZYX CHANGE METHOD DEDICATED SOLELY TO PROFIT FROM CHANGE BY TRADING AND INVESTING VERIFIABLE PERFORMANCE RECORD Every closed trade since 2007, without exception, is included in the performance results. Number of winning positions: 162 Number of losing positions: 10 Average annualized % return per position: 296.77% ………………Check out details .

Read More »

SHORT SELL $GENZ RIGHT HERE INTO STRENGTH AROUND $51.80 FOLLOWING DRUG APPROVAL

www.thearorareport.com THE ARORA REPORT, Ltd. HOME OF THE UNIQUE ZYX CHANGE METHOD DEDICATED SOLELY TO PROFIT FROM CHANGE BY TRADING AND INVESTING VERIFIABLE PERFORMANCE RECORD Every closed trade since 2007, without exception, is included in the performance results. Number of winning positions: 162 Number of losing positions: 10 Average annualized % return per position: 296.77% ………………Check out details .

Read More »

CONTINUE TO INCREASE HEDGES ON SHORT ALLOCATIONS IN BOTH ALLOCATION MODELS BASED ON TECHNICALS AS THE MARKET GOES LOWER

www.thearorareport.com THE ARORA REPORT, Ltd. HOME OF THE UNIQUE ZYX CHANGE METHOD DEDICATED SOLELY TO PROFIT FROM CHANGE BY TRADING AND INVESTING VERIFIABLE PERFORMANCE RECORD Every closed trade since 2007, without exception, is included in the performance results. Number of winning positions: 162 Number of losing positions: 10 Average annualized % return per position: 296.77% ………………Check out details .

Read More »

LOCK IN PROFITS ON $FAZ

As of this writing, $FAZ is at $16.17. We suggest taking partial profits right here and tight trailing stops on the rest. The trigger for this trade according to the ZYX Change Method was price action of European banks in European markets diverging from price action of US financials in the pre-market in US. www.thearorareport.com THE ARORA REPORT, Ltd. HOME OF THE UNIQUE ZYX CHANGE METHOD DEDICATED SOLELY TO PROFIT FROM CHANGE BY TRADING AND INVESTING VERIFIABLE PERFORMANCE RECORD Every closed trade since 2007, without exception, is included in the performance results. Number of winning positions: 162 Number of losing

Read More »

AI is power hungry. Investors will make a fortune from nuclear power for AI.
Get the list of 12 nuclear power stocks to grab your share of the profits.

AI is power hungry. Investors will make a fortune from nuclear power for AI.

Get the list of 12 nuclear power stocks to grab your share of the profits.

Big Tech is investing billions

Making A Fortune
In Nuclear Energy

Golden Age of Nuclear Energy

Skip to content